David M. Ashley

17.7k citations

236 papers · 9.1k indexed · 3 hit papers · h-index 46

Impact in

Genetics top 0.1%
- Glioma Diagnosis and Treatment
Immunology top 1%
- Immunotherapy and Immune Responses

Papers in

Genetics 82
- Glioma Diagnosis and Treatment 80
Immunology 46
- Immunotherapy and Immune Responses 22

Co-authors: Henry S. Friedman Mustafa Khasraw Aaron C. Tan Giselle Y. López Michael D. Malinzak John H. Sampson Darell D. Bigner Laura P. Hale
Journals: Neuro-Oncology (45 papers)Journal of Clinical Oncology (25 papers)Neuro-Oncology Advances (7 papers)Pediatric Blood & Cancer (7 papers)Clinical Cancer Research (6 papers)
Partner nations: United States Australia Canada

In The Last Decade

David M. Ashley

220 papers receiving 8.9k citations

Hit Papers

align trajectories log scale

Management of glioblastoma: State of the art and future directions 2020 · 1.4k citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2020 CA A Cancer Journal for Clinicians
2019 Nature reviews. Cancer
2018 New England Journal of Medicine

Peers

Countries citing papers authored by David M. Ashley

Since Specialization

Citations

This map shows the geographic impact of David M. Ashley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David M. Ashley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David M. Ashley more than expected).

Fields of papers citing papers by David M. Ashley

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David M. Ashley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David M. Ashley. The network helps show where David M. Ashley may publish in the future.

Co-authors

The 25 scholars most cited alongside David M. Ashley, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with David M. Ashley Line = papers co-authored together David M. Ashley links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Resilience and Vulnerabilities of Tumor Cells under Purine Shortage Stress Clinical Cancer Research ·Jianpeng Yu, Chen Jin, Cheng Su, David Moon, Michael A. Sun, Hong Zhang, Xue Jiang, Fan Zhang, Nomingerel Tserentsoodol, Michelle Bowie, Christopher J. Pirozzi, Daniel J. George, Robert Wild, Xia Gao, David M. Ashley, Yiping He, Jiaoti Huang	2025	0
2	NIMG-77. MRI PHENOMENON OF PUNCTATE ENHANCING LESIONS IN PATIENTS TREATED WITH IDH INHIBITORS Neuro-Oncology ·Michal Nisnboym Ziv, Mallika Patel, Maria Minor, Margaret Johnson, Kristen A. Batich, Justin Low, Madison L Shoaf, Mustafa Khasraw, Annick Desjardins, Henry S. Friedman, David M. Ashley, Katherine B. Peters	2024	0
3	Taking the STING out of radiotherapy: STING checkpoints mediate radiation resistance Journal of Clinical Investigation ·Michael C. Brown, Justin Low, Michelle Bowie, David M. Ashley	2024	1
4	Cancer-associated SMARCAL1 loss-of-function mutations promote alternative lengthening of telomeres and tumorigenesis in telomerase-negative glioblastoma cells Neuro-Oncology ·Heng Liu, Cheng Xu, Bill H. Diplas, Alexandrea Brown, Laura M. Strickland, Haipei Yao, Jinjie Ling, Roger E. McLendon, Stephen T. Keir, David M. Ashley, Yiping He, Matthew S. Waitkus	2023	11
5	Intratumor childhood vaccine-specific CD4⁺ T-cell recall coordinates antitumor CD8⁺ T cells and eosinophils Journal for ImmunoTherapy of Cancer ·Michael C. Brown, Georgia M. Beasley, Zachary P. McKay, Yuanfan Yang, Annick Desjardins, Dina Randazzo, Daniel Landi, David M. Ashley, Darell D. Bigner, Smita K. Nair, Matthias Gromeier	2023	4
6	Physician, patient, and caregiver support for a formal certification in pediatric neuro-oncology: A survey-based report from the SNO pediatrics working group Neuro-Oncology Advances ·Holly Lindsay, Sylvia Cheng, Paul G. Fisher, Katherine B. Peters, Kyle M. Walsh, David M. Ashley, Annie Huang	2023	1
7	A Pilot Study Omitting Radiation in the Treatment of Children with Newly Diagnosed Wnt-Activated Medulloblastoma Clinical Cancer Research ·Kenneth J. Cohen, Vasu Munjapara, Dolly Aguilera, Robert C. Castellino, Stacie Stapleton, Daniel Landi, David M. Ashley, Fausto J. Rodríguez, Cynthia Hawkins, Edward Yang, Wendy B. London, Susan Chi, Pratiti Bandopadhayay	2023	9
8	The Enduring Effects of COVID for Cancer Care: Learning from Real-Life Clinical Practice Clinical Cancer Research ·Alex Broom, Leah Williams Veazey, Katherine Kenny, Imogen Harper, Michelle Peterie, Alexander Page, Nicole Cort, Jennifer Durling, Eric Lipp, Aaron C. Tan, Kyle M. Walsh, Brent A. Hanks, Margaret Johnson, Amanda E.D. Van Swearingen, Carey K. Anders, David M. Ashley, Mustafa Khasraw	2023	7
9	Use, access, and initial outcomes of off-label ivosidenib in patients with IDH1 mutant glioma Neuro-Oncology Practice ·Katherine B. Peters, Candice Alford, Amy Heltemes, Alicia Savelli, Daniel Landi, Gloria Broadwater, Annick Desjardins, Margaret Johnson, Justin Low, Mustafa Khasraw, David M. Ashley, Henry S. Friedman, Mallika Patel	2023	11
10	Clinical Applications of Immunotherapy for Recurrent Glioblastoma in Adults Cancers ·Meagan Olivet, Michael C. Brown, Zachary J. Reitman, David M. Ashley, Gerald A. Grant, Yuanfan Yang, James M. Markert	2023	12
11	Spiritual well-being and its association with health-related quality of life in primary brain tumor patients Neuro-Oncology Practice ·Dina Randazzo, Frances McSherry, James E. Herndon, Mary Lou Affronti, Eric Lipp, Elizabeth Miller, Sarah Woodring, Patrick Healy, Jennifer Jackman, Brian T. Crouch, Annick Desjardins, David M. Ashley, Henry S. Friedman, Katherine B. Peters	2021	15
12	Primary brain tumor patients admitted to a US intensive care unit: a descriptive analysis CNS Oncology ·Jennifer Kang, Christa B. Swisher, Evan Buckley, James E. Herndon, Eric Lipp, John P. Kirkpatrick, Annick Desjardins, Henry S. Friedman, Margaret Johnson, Dina Randazzo, David M. Ashley, Katherine B. Peters	2021	3
13	Viral infection of cells within the tumor microenvironment mediates antitumor immunotherapy via selective TBK1-IRF3 signaling Nature Communications ·Michael C. Brown, Mubeen Mosaheb, Malte Mohme, Zachary P. McKay, Eda K. Holl, Jonathan P. Kastan, Yuanfan Yang, Georgia M. Beasley, Esther Hwang, David M. Ashley, Darell D. Bigner, Smita K. Nair, Matthias Gromeier	2021	50
14	Genetically stable poliovirus vectors activate dendritic cells and prime antitumor CD8 T cell immunity Nature Communications ·Mubeen Mosaheb, Elena Y. Dobrikova, Michael C. Brown, Yuanfan Yang, Jana M. Cable, Hideho Okada, Smita K. Nair, Darell D. Bigner, David M. Ashley, Matthias Gromeier	2020	29
15	The role of chemotherapy in the treatment of central neurocytoma CNS Oncology ·Margaret Johnson, John P. Kirkpatrick, Mallika Patel, Annick Desjardins, Dina Randazzo, Henry S. Friedman, David M. Ashley, Katherine B. Peters	2019	12
16	A RANDOMIZED PHASE II TRIAL OF VELIPARIB (V), RADIOTHERAPY (RT) AND TEMOZOLOMIDE (TMZ) IN PATIENTS (PTS) WITH UNMETHYLATED MGMT (uMGMT) GLIOBLASTOMA (GBM): THE VERTU STUDY Neuro-Oncology ·Mustafa Khasraw, Kerrie L. McDonald, Mark Rosenthal, Zarnie Lwin, David M. Ashley, Helen Wheeler, Elizabeth Barnes, Matthew Foote, Eng‐Siew Koh, Erik P. Sulman, Michael Back, Michael E. Buckland, Hao‐Wen Sim, Lauren Fisher, Robyn Leonard, Merryn Hall, Sonia Yip, John Simes	2019	1
17	Complementary and integrative health interventions and their association with health-related quality of life in the primary brain tumor population Complementary Therapies in Clinical Practice ·Dina Randazzo, Frances McSherry, James E. Herndon, Mary Lou Affronti, Eric Lipp, Charlene Flahiff, Elizabeth Miller, Sarah Woodring, Susan Boulton, Annick Desjardins, David M. Ashley, Henry S. Friedman, Katherine B. Peters	2019	8
18	“Cancer 2015”: A Prospective, Population-Based Cancer Cohort—Phase 1: Feasibility of Genomics-Guided Precision Medicine in the Clinic Journal of Personalized Medicine ·John P. Parisot, Heather Thorne, Andrew Fellowes, Ken Doig, Mark Lucas, John J. McNeil, Brett Doble, Alexander Dobrovic, Thomas John, Paul A. James, Lara Lipton, David M. Ashley, Theresa Hayes, Paul J. McMurrick, Gary Richardson, Paula Lorgelly, Stephen B. Fox, David M. Thomas	2015	8
19	Machine-learning prediction of cancer survival: a retrospective study using electronic administrative records and a cancer registry BMJ Open ·Sunil Gupta, Truyen Tran, Wei Luo, Dinh Phung, Richard L. Kennedy, A. Broad, David Campbell, David Kipp, Madhu Singh, Mustafa Khasraw, Leigh Matheson, David M. Ashley, Svetha Venkatesh	2014	83
20	Induction Chemotherapy and Conformal Radiation Therapy for Very Young Children With Nonmetastatic Medulloblastoma: Children's Oncology Group Study P9934 Journal of Clinical Oncology ·David M. Ashley, Thomas E. Merchant, Douglas Strother, Tianni Zhou, Patricia K. Duffner, Peter C. Burger, Douglas C. Miller, N. C. Lyon, Melanie J. Bonner, Michael E. Msall, Allen Buxton, Russell Geyer, Larry E. Kun, Lee Coleman, Ian F. Pollack	2012	67

About David M. Ashley

David M. Ashley is a scholar working on Genetics, Immunology, Neurology, Oncology and Biotechnology, having authored 236 papers that have together received 9.1k indexed citations. Recurring topics across this work include Glioma Diagnosis and Treatment (80 papers), Immunotherapy and Immune Responses (22 papers), Neuroblastoma Research and Treatments (21 papers), Childhood Cancer Survivors' Quality of Life (18 papers), Brain Metastases and Treatment (16 papers), Chromatin Remodeling and Cancer (16 papers), Cancer Research and Treatments (13 papers) and Epigenetics and DNA Methylation (12 papers). The work is most often cited by research in Genetics (3.1k citations), Immunology (1.9k citations), Oncology (2.3k citations), Cancer Research (1.0k citations) and Neurology (917 citations). David M. Ashley has collaborated with scholars based in United States, Australia and Canada. Frequent co-authors include Henry S. Friedman, Mustafa Khasraw, Aaron C. Tan, Giselle Y. López, Michael D. Malinzak, John H. Sampson, Darell D. Bigner, Laura P. Hale, Peter E. Fecci and Michael D. Gunn. Their work appears in journals such as Neuro-Oncology, Journal of Clinical Oncology, Neuro-Oncology Advances, Pediatric Blood & Cancer and Clinical Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact